Parmax Pharma Limited Share Price

Parmax Pharma Limited Share Price

BSE: 540359
|
Pharmaceuticals
|
S Cap
₹ 132.45
+₹1.30 (0.99%)
1D
Last updated 31 Aug, 2026, 15:15 IST

Parmax Pharma Limited Share Price Today

As of 5 Sep 2026, Parmax Pharma Limited share price is ₹132.45. The stock opened at ₹132.45, compared to its previous close of ₹131.15. During today's trading session, Parmax Pharma Limited share price moved in the range of ₹132.45 to ₹132.45, with an average price of ₹132.45 for the day. Looking at its last 52-week, the stock has touched a low of ₹22.60 and a high of ₹132.45.

₹132.45
0.99% up today
₹132.45
1D LOW
1D HIGH

Parmax Pharma Limited Returns Calculator

Circuit
L
H
₹131.15
₹133.75
52-week
L
H
₹22.60
₹132.45

About Parmax Pharma Limited

Parmax Pharma Limited Share Price
ISIN
INE240T01014
Sector Market Cap
₹ 91.11 Cr

Parmax Pharma Ltd is an India-based company, which is engaged in active pharmaceutical ingredients (API) and contract manufacturing operations (CMO) business. It uses quality by design techniques to produce complex molecules enabling customers to create formulations. The Company’s manufacturing units run in accordance with current good manufacturing practices (cGMP). Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Ormeloxifene Hydrochloride I.P., Milnacipram HCl, Calciumpoly Carbophil usp, Levosulpride, Paliperidone, Edaravone, Lacosamide, Iloperidone, Prasugrel HCl, 2-Acetyl Thiophene, Morpholine Hydrochloride, Camphor Sulfonyl Chloride, ISB-I (2-Chlorobenzaldehyde-5-Sulfonic acid disodium salt), Benzaldehyde-2, 5-Di-Sulfonic acid disodium salt, 2-picolinoxylidide, 4-Octyl amino pyridine (4-OAP), Sitagliptin phosphate Monohydrate API, Solifenacin Succinate API, Vilazodone Hydrochloride API, and Azelnidipine API.

Parmax Pharma Limited Financial Highlights

  • Revenue: Parmax Pharma Limited reported revenue of ₹12.16 crore in FY26 vs ₹28.24 crore in FY25. It showed a decrease of 56.94% on a yearly basis.
  • Operating Profit: Parmax Pharma Limited reported an operating loss of ₹5.85 crore in FY26 vs ₹2.40 crore in FY25. It showed a decrease of 143.75% on a year-on-year basis.
  • Net Profit: Parmax Pharma Limited reported a net loss of ₹4.16 crore in FY26 vs ₹2.09 crore in FY25. It showed a decrease of 99.04% on a yearly basis.

Parmax Pharma Limited Quarterly Result Highlights

  • Parmax Pharma Limited reported revenue of ₹10.30 crore in Jun 2026, compared with ₹3.34 crore in Mar 2026, representing an increase of 208.38% on a quarter-on-quarter (QoQ) basis.
  • Parmax Pharma Limited reported an operating profit of ₹2.20 crore in Jun 2026, compared with ₹2.27 crore in Mar 2026, representing an increase of 196.92% on a quarter-on-quarter (QoQ) basis.
  • Parmax Pharma Limited reported a profit of ₹2.20 crore in Jun 2026, compared with ₹0.58 crore in Mar 2026, reflecting an increase of 479.31% on a QoQ basis.
  • The earnings per share (EPS) of Parmax Pharma Limited stood at ₹5.60 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
30.80%
FII
0.00%
Other DII
0.00%
Retail and other
69.20%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20250.00%
Dec 20250.00%
Mar 20260.00%
Jun 20260.00%
Mkt Cap Cr
91.11
P/E
-76.12
P/B
19.83
ROE
67.65%
D/E
-1.87
ROCE
-85.76%
Div. Yield
0.00%
EPS(TTM)
-11.12
Turnover
0.66
EV/EBITDA
-268.36
Net Margin
0.00%
Op. Margin
0.00%
ROA
-4.24%
Quick Ratio
0.00
Curr. Ratio
0.74
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Parmax Pharma outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Parmax Pharma appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,56,833.0037.605.4513.74%0.6117.33%93.240.84%0.4810.90
Divis Laboratories2,45,426.0082.5914.4115.32%0.0019.56%629.490.33%0.5598.19
Torrent Pharmaceuticals1,87,320.0085.5721.9425.49%1.6913.85%222.760.70%0.4958.70
Zydus Lifesciences1,13,217.0024.354.1218.59%0.3117.35%237.300.09%0.3335.38
Cipla1,12,212.0033.343.2511.27%0.0014.95%423.360.94%0.4543.52
Laurus Labs99,417.5091.1818.7616.77%0.4016.14%97.200.11%0.6713.72
Lupin97,626.3017.394.3023.76%0.0424.88%659.000.85%0.57129.18
Mankind Pharma96,179.6046.525.9011.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories96,405.5030.262.5311.07%0.1812.54%377.950.69%0.4138.68
Aurobindo Pharma93,614.0025.642.519.25%0.1911.76%394.820.24%0.3841.58

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Parmax Pharma Limited Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹28.20₹11.05₹15.42₹18.25
Other Income₹0.04₹0.05₹0.04₹0.06
Total Revenue₹28.24₹11.10₹15.46₹18.31
Total Expenses₹29.57₹16.76₹15.42₹18.01
Profit Before Tax-₹2.40-₹5.66₹0.05₹0.30
Tax-₹0.30₹0.09₹0.15₹0.16
Profit After Tax-₹2.09-₹5.75-₹0.10₹0.14
EPS - Basic-₹5.60-₹34.56-₹0.28₹0.38
EPS - Diluted-₹5.60-₹34.56-₹0.28₹0.38

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax-₹2.40-₹5.66₹0.05₹0.30
Income before WC changes-₹0.59-₹4.07₹1.74₹2.02
Change in Assets-₹4.19₹1.80-₹1.23₹2.66
Change in Liabilities₹3.83₹2.08-₹0.18-₹3.93
Change in WC-₹0.36₹3.88-₹1.41-₹1.27
Cash flow from Operations-₹0.96-₹0.20₹0.33₹0.75
Cash flow from Investing-₹0.70-₹1.59-₹0.94-₹1.53
Cash flow from Financing₹1.40₹1.43-₹0.04-₹0.91
Total Cash Flow-₹0.26-₹0.36-₹0.65-₹1.69
Cash (Start of the year)₹0.05₹0.41₹1.05₹2.75
Cash (End of the year)-₹0.21₹0.05₹0.41₹1.05

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹8.75₹9.56₹10.08₹11.42
Current Assets₹10.00₹5.77₹7.53₹6.56
Total Assets₹18.75₹15.33₹17.61₹17.97
Current Liabilities₹13.04₹9.21₹7.14₹7.31
Net Current Asset-₹3.03-₹3.44₹0.39-₹0.75
Non-Current Liabilities₹7.70₹6.01₹4.62₹4.70
Equity Capital-₹1.99₹0.11₹5.86₹5.96
Total Equity & Liabilities₹18.75₹15.33₹17.61₹17.97
* All values are in INR Crore
Qty
Bid
8851
132.45
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 8851
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
5
Neutral
1
Bullish
2
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
88.04
Bullish
ATR (14)
2.13
Neutral
STOCH(9,6)
100
Bearish
STOCH RSI (14)
100
Bearish
ADX(9)
61.79
Bearish
UO(9)
96.39
Bearish
ROC(12)
24.07
Bullish
WillR(14)
0
Bearish
Period
Simple value
Exponential vaue
5D
129.17
128.89
10D
123.49
124.09
20D
114.65
116.71
50D
98.24
98.5
100D
67.25
78.51
Volume trend — traded volume by day
31 Aug0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Parmax Pharma Limited Share Price
Parmax Pharma Limited
Pharmaceuticals
Add Stock
Add Another

Parmax Pharma Limited Share Price FAQs

Parmax Pharma Limited share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837